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Despite 200 years of use, the ability of digitalis glycosides to 
improve exercise capacity in patients with congestive heart failure 
remains controversial, partly because of imprecise end points and 
suboptimal study design. Therefore, this question was examined 
in 10 ambulatory patients (8 men and 2 women) aged 46 to 70 
years (mean 57.8) in sinus rhythm with mild to moderate chronic 
stable congestive heart failure due to coronary artery disease and 
systolic left ventricular dysfunction (ejection fraction 32 ± 12). All 
underwent maximal treadmill exercise with respiratory gas anal-
ysis and upright cycle ergometry with gated radionuclide angiog-
raphy after 4 weeks of digoxin or placebo therapy, administered in 
a randomized double-blind crossover protocol. 
Neither treadmill exercise duration (7.7 ± 2.3 versus 7.3 ± 
2.7 min) nor peak oxygen consumption (18.7 ± 3.7 versus 18.4 ± 
5.4 ml/kg per min) differed between digoxin and placebo regi-
mens. However, the change in peak oxygen consumption induced 
by digoxin was inversely related to the peak oxygen consumption 
during placebo therapy (r = -0.64, P < 0.05). At maximal 
treadmill effort, heart rate (138 ± 16 versus 141 ± 21 beats/min), 
oxygen pulse (10.3 ± 2.1 versus 9.9 ± 2.2 ml/beat), ventilation 
(40.3 ± 10.6 versus 42.0 ± 10.8 liters/min) and ventilatory 
equivalent (29.4 ± 4.8 versus 31.5 ± 6.8) did not differ between 
digoxin and placebo treatment, although systolic blood pressure 
Although almost all patients with congestive heart failure 
manifest some degree of abnormal systolic or diastolic left 
ventricular performance at rest. the overall ability of their 
circulatory system to meet metabolic demands at rest is 
usually adequate. Physical exertion. however. typically elic-
its a significant functional impairment. characterized by a 
decreased oxygen consumption at maximal effort (I). Peak 
treadmill oxygen consumption represents the integrated abil-
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was higher during digoxin therapy (163.0 ± 23.1 versus 153.2 ± 
25.3 mm Hg. p < 0.05). 
Left ventricular ejection fraction at rest (32 ± 12 versus 29 ± 
12) and maximal cycle work load achieved (75 ± 32 versus 75 ± 
28 W) were not affected by glycoside treatment, but ejection 
fraction and systolic blood pressure at maximal effort were both 
higher during digoxin than during placebo therapy (32 ± 8 versus 
27 ± 9. P < 0.05, and 177 ± 25 versus 165 ± 21 mm Hg, p < 0.05, 
respectively). The change in peak treadmill oxygen consumption 
and the change in peak ergometric left ventricular ejection 
fraction induced by digoxin were not related (r = - .035, P = NS). 
Therefore, in ambulatory patients with coronary artery disease 
and chronic. predominantly mild to moderate heart failure, 
systolic left ventricular dysfunction and sinus rhythm, mainte-
nance digoxin treatment did not elicit an increase in aerobic 
capacity despite improvement in left ventricular performance 
during exercise. Nevertheless, the inverse relation between the 
peak oxygen consumption during placebo administration and the 
change in this variable elicited by digoxin suggests that exercise 
testing with respiratory gas analysis may provide a rational basis 
for identifying ambulatory patients with heart failure who are 
likely to benefit from maintenance digoxin therapy. 
(j Am Coll CardioI1991;17:743-Sl) 
ity of the cardiopulmonary system to deliver oxygen to the 
exercising muscles as well as the ability of the muscles to 
utilize the delivered oxygen. Measurement of peak treadmill 
oxygen consumption provides an objective and reproducible 
noninvasive method of quantifying exercise performance in 
patients with congestive heart failure (I) and in normal 
persons (2). Recent studies (3. 4) show that peak oxygen 
consumption is a strong independent predictor of mortality 
in persons with congestive heart failure. Therefore, any 
therapeutic intervention in congestive heart failure must be 
evaluated not only for its effect on left ventricular perfor-
mance at rest. but also for its ability to improve functional 
capacity-that is. exercise tolerance. 
Although digitalis glycosides have been used for 2 centu-
ries. their ability to augment the impaired exercise capacity 
and left ventricular performance of patients with congestive 
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heart failure is unproved. Several investigators (5-7) re-
ported no impairment in maximal treadmill walking time 4 to 
12 weeks after study patients discontinued maintenance 
digoxin therapy. Three recent multicenter trials (8-10), 
however, showed longer treadmill walking times in digoxin-
treated than in placebo-treated patients. The confounding 
effects of patient motivation, learning and training effects of 
repeated exercise tests and the unblinded nature of some of 
these studies (6,7) raise questions regarding their interpreta-
tion, particularly because oxygen consumption was not 
measured in any of these studies. 
Whether digoxin can enhance left ventricular perfor-
mance during aerobic exercise is also controversial. Prior 
investigators (11, 12), using invasive methods, demonstrated 
improved hemodynamics during sub maximal bicycle exer-
cise after several weeks of digoxin therapy. Radionuclide 
angiography, introduced during the past decade as an accu-
rate noninvasive tool for assessing exercise left ventricular 
function, has not been used to assess the inotropic efficacy of 
maintenance digoxin therapy in patients with congestive 
heart failure during exercise. Furthermore, the relation 
between digoxin-induced changes in exercise left ventricular 
function and aerobic performance is unknown. 
The current study was designed to investigate the effect 
of maintenance digoxin therapy on both maximal aerobic 
performance and exercise left ventricular function in pa-
tients with congestive heart failure, by using respiratory gas 
analysis and radionuclide angiography, respectively. Be-
cause heart failure is usually secondary to coronary artery 
disease in the United States (13), we restricted the present 
study to a relatively homogeneous group of middle-aged and 
older patients with chronic congestive heart failure and left 
ventricular systolic dysfunction secondary to coronary ar-
tery disease, and used a randomized, double-blind, placebo-
controlled, crossover design. 
Methods 
Study patients. Patients were selected from the outpa-
tient medical and cardiac clinics of Francis Scott Key 
Medical Center (formerly called Baltimore City Hospitals). 
All patients had at least one radiographically documented 
episode of left-sided heart failure, unassociated with an 
acute ischemic event or major systemic insult. Chronic 
congestive heart failure was documented in each patient by 
residual clinical symptoms or signs of pulmonary venous 
hypertension, or both; left ventricular enlargement by recent 
echocardiogram or radionuclide ventriculogram; and a scin-
tigraphic left ventricular ejection fraction <50%. Only pa-
tients whose heart failure was due to coronary artery disease 
were considered for study. Coronary artery disease was 
defined angiographically by the presence of 2::50% stenosis 
in one or more coronary arteries or by a history of a 
documented myocardial infarction if catheterization data 
were unavailable. Patients with significant valvular disease 
or a history of alcohol abuse were excluded even if coronary 
lACC Vol. 17. No.3 
March I, 1991:743-51 
artery disease was present. Patients with atrial fibrillation or 
a history of atrial tachyarrhythmia were excluded. as were 
those with a myocardial infarction within the preceding 6 
months. Furthermore. only patients capable of maximal 
treadmill exercise without limitation by angina pectoris, 
claudication or pulmonary. orthopedic or neurologic disabil-
ity were studied. To ensure clinical stability, we required 
that a patient's cardiac medications remain unchanged for at 
least 3 months before study entry. Before a patient entered 
the study, we adjusted the digoxin dosage as necessary to 
achieve a therapeutic serum level of 1 to 2 ng/ml at least 6 
hours after the previous dose. The study was approved by 
the Institutional Review Board of the Francis Scott Key 
Medical Center. 
Protocol. The study was carried out in three visits to the 
laboratory. During the initial visit, the protocol was thor-
oughly explained and each patient gave informed consent. 
The patients were then familiarized with the treadmill and 
respiratory gas exchange apparatus. Maximal, graded, 
symptom-limited exercise was then performed, with use of a 
modified Balke protocol in which the treadmill incline was 
increased by 3% every 2 min, starting from the horizontal, to 
exhaustion. Treadmill speed was adjusted to enable the 
patients to walk for at least 5 min; treadmill speed remained 
constant throughout exercise. The electrocardiogram (ECG) 
was monitored continuously in leads a VF, V 1 and V 5 
throughout exercise. A 12 lead ECG was recorded and 
indirect brachial artery blood pressure was measured during 
the final 30 s of each exercise stage and every 2 min during 
a 6-min recovery period. The patient's expired gases were 
collected in stainless steel Tissot spirometers for the entire 
2nd min of each exercise work load. If a full 60 s collection 
could not be obtained at maximal effort. a shorter collection 
period was used (at least 30 s). Gases were analyzed imme-
diately after collection with an Applied Electrochemistry 
oxygen analyzer and a Beckman LB-2 carbon dioxide ana-
lyzer. both of which were calibrated with standard gases 
immediately before the test (14). 
The next day. patients reported to the Nuclear Medicine 
Department, where gated blood pool scans were performed 
at rest after in vivo labeling of red blood cells by technetium-
99m as previously described (15). After supine imaging in the 
anterior and best septal left anterior oblique views using a 
Technicare model 550 camera with a general purpose colli-
mator, the patient assumed an upright sitting position on an 
adjustable exercise table (Atomic Products, Inc.) with his or 
her feet resting on the pedals of an electronically braked 
cycle ergometer (Collins, Inc.). The gamma camera was 
again positioned in the left anterior oblique view for optimal 
separation of the ventricles and an image was acquired over 
2 min. Once this 2 min upright image of the left ventricular 
was technically satisfactory, the cycle exercise protocol was 
begun. Exercise was begun at 25 Wand increased by 25 W 
increments every 3 min until exhaustion. A constant pedal 
speed of 60 rpm was maintained throughout. Cardiac imag-
ing was performed during the last 2 min of each 3 min stage. 
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A 12 lead ECG was obtained during each minute of exercise, 
as was a cuff blood pressure during the final minute of each 
work load. If we suspected that the final work load could not 
be maintained for a full 3 min, imaging was begun earlier in 
the stage to obtain maximal count information. 
Each patient's rest and exercise-gated blood pool scan 
was read by a single experienced nuclear medicine physician 
who did not know the therapy being administered. Left 
ventricular ejection fraction was calculated in the left ante-
rior oblique view by a Technicare model 550F computer with 
use of a semi-automated count-based technique after back-
ground subtraction (15). 
After completion of the two baseline exercise tests, the 
patients were randomized to receive either digoxin or an 
identical placebo tablet and were instructed to take the study 
medication in place of their regular digoxin. Both the pa-
tients and the investigators were unaware of the tablets' 
identity. Patients returned for their next visit 4 weeks later 
and underwent repeat treadmill and cycle exercise testing, 
exactly as previously described. At the conclusion of the 
visit, they were crossed over to the alternate regimen and 
were asked to return again in 4 weeks, when a third and final 
pair of exercise tests was administered in identical fashion. 
Data analysis. The following variables were compared at 
maximal treadmill exercise between the digoxin versus pla-
cebo periods: exercise duration, maximal heart rate, peak 
systolic blood pressure, minute ventilation, peak oxygen 
consumption, ventilatory equivalent, defined as the ratio of 
ventilation to peak oxygen consumption, and oxygen pulse, 
defined as peak oxygen consumption divided by maximal 
heart rate. To examine the effect of digoxin on submaximal 
exercise performance, we compared the heart rate, oxygen 
pulse and ventilatory equivalent responses at submaximal 
work loads during digoxin and placebo regimens. 
During upright cycle exercise, the following variables 
were compared between digoxin and placebo regimens: 
exercise duration, maximal work load, maximal heart rate, 
peak systolic blood pressure, left ventricular ejection frac-
tion at maximal effort and the change in left ventricular 
ejection fraction from rest to exercise. 
Control SUbjects. As a standard for comparison, a control 
group of age- and gender-matched healthy volunteers from 
the Baltimore Longitudinal Study on Aging (16) was derived, 
three controls for each patient, to define normal indices of 
respiratory gas exchange and left ventricular performance 
during exercise. Each control subject was clinically free of 
heart disease and had a normal electrocardiographic re-
sponse to maximal treadmill exercise. 
Statistical analysis. Values are mean ± SD. Values in 
healthy control subjects and patients with congestive heart 
failure were compared by an unpaired t test. Comparisons 
between digoxin and placebo therapies at maximal effort 
were made using a paired t test; similar comparisons at 
submaximal work loads were made by repeated measures 
analysis of variance. Linear regression analysis was used to 
assess the relationship between physiologic variables. For 
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all analyses, a p value :5 0.05 by two-tailed testing was 
considered significant. 
Results 
Of the 12 patients enrolled in the study, two failed to 
complete all three visits: one subject was hospitalized for an 
acute attack of gouty arthritis 1 week after randomization to 
digoxin and the other had clinical exacerbation of congestive 
heart failure during the placebo phase and resumed digoxin 
on his own before exercise testing could be performed. 
Clinical characteristics. The eight men and two women 
who constituted the final study group were 46 to 70 years old 
(mean 57.8). All 10 were receiving maintenance digoxin 
0.125 to 0.50 mg/day (mean 0.28 ± 0.09), which they had 
been taking for 0.5 to 8 years. Congestive heart failure was 
due to coronary artery disease in all 10 subjects, half of 
whom had a history of prior myocardial infarction. Among 
the five patients without a prior infarction, two had under-
gone coronary artery bypass grafting and three had coronary 
artery disease documented by cardiac catheterization. Eight 
of the patients were in New York Heart Association func-
tional class II and two were in class III. An S3 gallop was 
present in two subjects, basilar rales in two and mild jugular 
venous distention in five at the time of study. All patients 
were receiving maintenance diuretic therapy and five were 
receiving a vasodilator. Left ventricular ejection fraction at 
rest averaged 33 ± 12% on study entry. 
Baseline treadmill exercise performance and respiratory 
gas exchange (Table 1). Maximal heart rate, systolic blood 
pressure and respiratory gas exchange results achieved with 
treadmill exercise during the placebo phase in the patients 
with congestive heart failure and the control subjects were 
compared. Except for the ventilatory equivalent and systolic 
blood pressure, all values in the patients differed signifi-
cantly from those in the control subjects, indicating signifi-
cant impairment of aerobic capacity and maximal cardiopul-
monary performance in the patients. Similarly, maximal 
cycle workload achieved and left ventricular performance at 
rest and during upright cycle ergometry were markedly 
lower in the patients with congestive heart failure than in 
control subjects. 
Exercise was limited by dyspnea or fatigue in all patients 
throughout all phases of testing. Peak oxygen consumption 
was nearly identical during baseline testing with digoxin 
therapy before randomization (18.9 ± 4.0 mUkg per min) and 
during the digoxin phase of the study (18.7 ± 3.7 mllkg per 
min), with a mean difference of 0.2 ± 1.0 mllkg per min. A 
plateau of oxygen consumption, as defined by a leveling off 
of oxygen consumption with increasing workload, was 
achievable in six of the 10 patients. These patients tended to 
have a higher aerobic capacity than those not achieving a 
plateau (20.7 ± 2.5 versus 16.9 ± 5.3 ml/kg per min, p > 
0.10). 
Clinically, none of the 10 patients noted significant differ-
ences in heart failure symptoms or required adjustment of 
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Table 1. Comparison of Exercise Performance in 10 Study Patients and 30 Control Subjects 
CHF Patients Controls 
(n = 10) (n = 30) p 
Exercise performance 
Maximal heart rate (beats/min) 139.0 ± 19.0 162.0 ± 14.0 0.01 
Peak systolic BP (mm Hg) 167.8 ± 27.7 181.0 ± 25.1 NS 
Peak V02 (ml/kglmin) 18.6 ± 4.1 32.0 ± 4.6 0.0001 
O2 pulse (mllbeat) IOJ ± 2.6 15.3 ± 3.0 0.001 
Maximal ventilation (liters/min) 41.5 ± 12.4 72.3 ± 19.5 0.0001 
Ventilatory equivalent 28.9 ± 5.3 29.4 ± 4.8 NS 
Left ventricular performance during 
maximal upright cycle exercise 
Maximal work load (W) 72.9 ± 29.1 130.0 ± 33.7 0.0001 
Maximal heart rate (beats/min) 140.0 ± 23.2 148.7 ± 16.9 NS 
Peak systolic BP (mm Hg) 180.0 ± 21.1 195.4 ± 31.3 0.09 
L VEF at peak effort 33.0 ± 11.9 79.1 ± 8.6 0.0001 
Change in L VEF (peak minus rest) -0.1±5.7 15.9 ± 7.7 0.0001 
All values in this and subsequent tables represent mean ± SO. Values in patients are derived from baseline 
measurements during digoxin therapy. Control subjects are normal volunteers in the Baltimore Longitudinal Study 
of Aging who were matched for age and gender with the study patients. BP = blood pressure; CHF = congestive 
heart failure; L VEF = left ventricular ejection fraction; VOz = peak oxygen consumption. 
diuretic or vasodilator dosage between digoxin and placebo 
regimens. Body weight did not differ between digoxin (77.1 
± 14.1 kg) and placebo (7703 ± 14.9 kg) phases. Serum 
digoxin level averaged 1.4 ± OJ ng/ml during the digoxin 
phase of the study and was less than 0.5 ng/ml (the lower 
limit of reliable measurement in our laboratory) in all sub-
jects during placebo therapy. Pre-exercise sitting heart rate 
was similar during digoxin and placebo regimens (79.8 ± 
12.2 versus 8203 ± 12.9 beats/min, respectively). Sitting 
pre-exercise systolic blood pressure tended to be higher 
during digoxin than during placebo 027.6 ± 19.9 versus 
117.2 ± 19.3) therapies; the difference in systolic blood 
pressure, 10.4 ± 14.8 mm Hg, was significant (p < 0.05). 
Exercise performance during digoxin vs. placebo phases 
(Table 2). Neither exercise duration (7.7 ± 2.3 min versus 
703 ± 2.6 min) nor peak oxygen consumption achieved 
(18.7 ± 3.7 versus 18.4 ± 4.7 mllkg per min) differed between 
the digoxin and the placebo phases of therapy. Individual 
changes in peak oxygen consumption are shown in Figure I. 
If a real change in aerobic performance is defined by a 
change in peak oxygen consumption >2.0 mllkg per min, 
two patients improved with digoxin and two with placebo, 
and six showed no difference between regimens. A signifi-
cant inverse relationship existed between the change in peak 
oxygen consumption elicited by digoxin and the value during 
placebo (Fig. 2). Two of three patients whose peak oxygen 
consumption during placebo was <15 ml/kg per min im-
proved with digoxin therapy, whereas none of the seven with 
higher baseline peak oxygen consumption did so. Oxygen 
pulse, a general index of stroke volume, was also unaffected 
by digoxin at maximal effort (Fig. 3). Although systolic blood 
pressure at maximal effort was higher during digoxin ther-
apy, no difference between digoxin and placebo was demon-
strable for maximal heart rate, ventilation or ventilatory 
equivalent (Table 2). Furthermore, there was no significant 
relationship between the placebo values for any gas ex-
change variables and the change induced by digoxin. Serum 
digoxin level also bore no demonstrable relationship to the 
change in any variable between digoxin and placebo regi-
mens. 
Role of concomitant vasodilator therapy (Table 3). To 
determine whether concomitant vasodilator therapy might 
be masking the beneficial effects of digitalis on gas exchange. 
we compared the effects of digoxin in the five patients 
receiving vasodilator therapy and the five patients not re-
ceiving it. Although peak V02 and ventilation were similarly 
Table 2. Digoxin Versus Placebo Phases: Maximal Treadmill Exercise Results in 10 Patients 
Digoxin Placebo Difference p 
Duration (min) 7.7 ± 2.3 7.3 ± 2.7 0.4 ± 1.0 NS 
Peak V02 (ml/kg per min) 18.7 ± 3.7 18.4 ± 4.7 OJ ± 2.7 NS 
Heart rate (beats/min) 138.5 ± 16.2 141.0 ± 21.3 -2.5± 11.6 NS 
Systolic BP (mm Hg) 163.0 ± 23.1 153.2 ± 25.3 9.8 ± 13.6 0.05 
O2 pulse (mllbeat) 10.3 ± 2.1 9.9 ± 2.2 0.4 ± 1.2 NS 
Ventilation (liters/min) 40J ± 10.6 42.0 ± 10.8 -1.7±9.5 NS 
Ventilatory equivalent 29.4 ± 4.8 31.5 ± 6.8 -2.1 ± 5.8 NS 
Abbreviations as in Table I. 
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Figure 1. Comparison of peak oxygen consumption (V02) during 
treadmill exercise during digoxin and placebo regimens in the 10 
patients. Mean and SD for each regimen are also shown. 
unaffected by digitalis in the two groups, the change in 
oxygen pulse at maximal effort was significantly greater in 
patients receiving a vasodilator. This finding might be ex-
plained by the smaller baseline placebo value for oxygen 
pulse in this group. 
Results during submaximal work loads. To ascertain 
whether digoxin improves the efficiency of gas exchange at 
sub maximal work loads, which are more representative of 
everyday tasks than tests of maximal effort, we compared 
heart rate, oxygen pulse and ventilatory equivalent at 0%, 
3% and 6% treadmill elevations between digoxin and placebo 
phases in the eight subjects in whom these work loads were 
submaximal. No difference was apparent during digoxin and 
placebo therapies at these lower work loads (Fig. 4). 
Cardiac performance during maximal cycle exercise (Table 
4). Left ventricular ejection fraction at rest was 31.5 ± 12.0 
during the digoxin phase of therapy and 29.2 ± 12.1 during 
placebo (p = NS). Maximal upright cycle exercise capacity 
averaged an identical 75 W (range 25 to 125) during digoxin 
and placebo and was limited in all patients by dyspnea or 
Fi~~re 2. C~an~e in treadmill peak oxygen consumption (V02) 
elICIted by dIgoXIn versus peak V02 value during placebo therapy in 
10 patients. A significant inverse relationship is present. 
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Figure 3. Comparison of oxygen pulse, a general index of stroke 
volume, on digoxin and placebo therapy during treadmill exercise. 
Mean and SD for each regimen are also shown. 
muscular fatigue. The maximal work load achieved remained 
the same on both regimens in eight patients and differed by 
25 W in two, one of whom had a higher level during digoxin 
and a higher level during placebo therapy. Maximal heart 
rate did not differ between regimens. Peak systolic blood 
pressure was higher, however, with digoxin therapy. Despite 
this presumably higher afterload on digoxin treatment, left 
ventricular ejection fraction at maximal effort was signifi-
cantly higher than during placebo therapy. The presence or 
absence of vasodilator therapy did not affect the rest or 
exercise ejection fraction response to digoxin. Individual 
changes in left ventricular ejection fraction at exhaustion are 
shown in Figure 5. A modest inverse relationship was noted 
between peak left ventricular ejection fraction during pla-
cebo therapy and the change elicited by digoxin (r = -0.49, 
p < 0.2). However, there was no relationship between 
the change in peak left ventricular ejection reaction and 
the change in peak treadmill oxygen consumption elicited 
by digoxin therapy (r = - .035, p > 0.5). Among the nine 
patients who achieved a maximal work load greater than 
25 W, the left ventricular ejection fraction at 25 W was also 
augmented by digoxin (34 ± 13 versus 28 ± 10, p < 0.05). 
The small number of subjects reaching an exercise load 
greater than 75 W precluded meaningful comparison of left 
ventricular ejection fraction at other common submaximal 
work loads . 
Discussion 
Previous studies on the effect of digoxin on exercise perfor-
mance. Only in the past decade have investigators sought 
to objectively assess effect of digoxin on exercise perfor-
mance. The studies have reached conflicting results, depen-
dent on the end points used. Unblinded studies (6,7) and a 
prior blinded study in our laboratory (5) demonstrated no 
difference in treadmill exercise duration with or without 
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Table 3. Effect of Baseline Vasodilator Status on Response to Digoxin at Maximal Exercise 
in 10 Patients 
No 
Vasodilator Vasodilator 
(n = 51 (n = 51 p 
Peak VO, on placebo (ml/kg per mini 17.7 :+: 6.5 18.9:+: .1.1 NS 
Change in peak VO, (ml/kg rer mini 0,5 :+: 3.8 -(1.1 :+: U NS 
0, pulse on placebo (ml/beat) 9.1 :+: 1.9 10.6 :+: ~,5 D.05 
Change in 0, pulse (ml/beatl O.9:+: U -().()~ :+: 0.7 0.05 
Ventilation on placebo (liters/mini 41.1 :+: I~J 4~.9 :+: 10.4 NS 
Change in ventilation (liters/min) -1.6 :+: 8.6 -1.8:+: 6.1 NS 
Change in variables is calculated as digoxin value mimh placebo value. VO, = peak oxygen consumption. 
maintenance digoxin therapy. In another blinded study (17). 
digoxin administration was associated with a slight improve-
ment in a 6-minute walking test but no change in exercise 
duration during multistage cycle ergometry. Three recent 
large. placebo-controlled studies (8-10) of patients with 
Figure 4. Comparison of heart rate (A). oxygen pulse (8) and 
ventilatory equivalent (e) at suhmaximal treadmill effort during 
digoxin (closed circles) and placebo therapy (open circles). Values 
represent mean and SO. Two patients were excluded from the 
analysis at 5 minutes of exercise because this represented their 
maximal effort. No differences between digoxin and placebo are 
demonstrable by analysis of variance for any of these three varia-
bles. 
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predominantly functional class II and III heart failure re-
vealed modest increases in treadmill exercise duration with 
digoxin. but in two of these studies (8.1 0) the improvement 
did not reach statistical significance. Furthermore, in these 
three trials parallel digoxin and placebo treatment groups 
were studied: a more rigorous crossover protocol was used 
in the present investigation. Although the correlation of 
exercise duration with more objective measures of aerobic 
performance is reasonably good, observer bias during test 
administration, variability in patient motivation and a learn-
ing effect from repeated exercise testing may all influence 
exercise duration independent of true changes in aerobic 
capacity. 
Effect of digoxin on aerobic performance in heart failure. 
In the last few years, the feasibility of using respiratory gas 
exchange to measure aerobic performance in patients with 
congestive heart failure and the superiority of this method 
over conventional measurements of exercise duration 
have been demonstrated (1,18). The current study used 
measurements of both respiratory gas exchange and left 
ventricular systolic function during maximal aerobic exer-
cise, in a patient subset homogeneous for the presence of 
congestive heart failure and systolic dysfunction due to 
coronary artery disease: it thus provides a detailed physio-
logic assessment of the effect of digoxin on exercise perfor-
mance. Our most noteworthy finding was the overall lack of 
effect of digoxin on maximal exercise capacity, whether 
measured on a treadmill or a cycle ergometer. Peak oxygen 
consumption, exercise duration and maximal workload were 
indistinguishable between digoxin and placebo phases: max-
imal heart rate, oxygen pulse, ventilation and ventilatory 
equivalent were similarly unaffected by digoxin therapy. 
Nevertheless, within our small sample an inverse linear 
correlation was found between the change in peak oxygen 
consumption elicited by digoxin and the peak oxygen con-
sumption during placebo therapy. 
Previous studies using respiratory gas exchange to assess 
digoxin efficacy. Previous studies (19-21) have used respira-
tory gas exchange to assess the effect of maintenance 
digoxin therapy for congestive heart failure. McHaffie et al. 
(19). after achieving dry weight with furosemide in five 
patients with chronic congestive heart failure, found no 
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Table 4. Digoxin Versus Placebo Effects on Maximal Cycle Exercise Performance 
Duration (min) 
Maximal work load (W) 
Heart rate (beats/min) 
Systolic BP (mm Hg) 
LVEF 
Abbreviations as in Table 1. 
Digoxin 
8.7 ± 3.6 
75.1 ± 32.1 
130.5 ± 21.4 
176.5 ± 25.0 
31.9 ± 8.2 
added benefit from oral digoxin on symptoms or gas ex-
change during submaximal bicycle exercise; the effect 
on maximal aerobic capacity was not examined. More 
recently (20). in 15 patients with mild to moderate congestive 
heart failure. 1 month of digoxin therapy improved peak 
oxygen consumption from 585 to 716 mllmin during up-
right cycle ergometry; peak work load increased in parallel 
from 50 to 61.4 W. Although the patient population. study 
duration and exercise protocol were similar to those in our 
study, the greater mean baseline exercise capacity of our 
subjects (75 versus 50 W) may account for the difference in 
outcome. 
Probably most comparable to our protocol is a recently 
completed trial by Sullivan et al. (21) in 11 patients with 
functional class II and III heart failure. These investigators 
documented a deterioration in treadmill peak oxygen con-
sumption from 19.3 to 16.7 mllkg over 2 to 4 weeks when 
digoxin was discontinued in an unblinded fashion. Their 
patients differed from ours in several respects: in only half 
was coronary artery disease the cause of heart failure; the 
heart rate at rest was substantially higher (91 beats/min. 
versus 80 beats/min on digoxin in our study); and 10 of 11 
had a third heart sound. Although at first glance their results 
seem at odds with our own. closer examination of their 
individual patient data reveals a similar trend: all five pa-
tients with a baseline peak oxygen consumption of less than 
15 mllkg per min had improvement with digoxin, compared 
with only three of six with higher baseline oxygen consump-
tion. If we combine their data with our own. seven of eight 
patients with aerobic capacities below 15 mllkg per min 
showed improvement by at least 2 mllkg per min on digoxin. 
compared with 3 of 13 patients with higher baseline aerobic 
Figure 5. Effect of digoxin and placebo on radionuclide left ventric-
ular ejection fraction at maximal cycle exercise in the 10 patients. 
Mean ± SO on each regimen are shown. 
~ 60 p < .05 
'" 50 « w ~ a. Z 40 0 !~l i= (.) 30 « a: u.. 20 z 0 
i= 10 (.) 
w ..., 
w 0 
DIGOXIN PLACEBO 
Placebo Difference p 
8.6 ± 3.0 0.1 ± 1.4 NS 
75.0 ± 28.4 0.1 ± 12.4 NS 
131.7 ± 18.3 -1.2 ± 10.1 NS 
165.2 ± 21.0 11.3 ± 12.3 0.05 
27.2 ± 8.9 4.7 ± 6.2 0.05 
capacity (p < 0.02 by chi-square analysis). These results 
reinforce the concept of diagnostic heterogeneity in heart 
failure trials as delineated by Marantz et al. (22) and suggest 
that improvement in aerobic capacity anticipated from intro-
duction of digitalis is inversely proportional to the aerobic 
capacity before digitalis therapy. Although the presence or 
absence of vasodilator therapy in our sample had no demon-
strable influence on the response of peak V02 to digitalis, the 
effect of digoxin on oxygen pulse was greater in vasodilator-
treated patients, probably because of their lower initial 
value. 
Because maximal aerobic capacity may be less relevant 
to everyday living than the ease of performing submax-
imal tasks, we also compared heart rate and indexes of 
respiratory gas exchange at submaximalloads. In this setting 
as well. digoxin had no effect on heart rate, oxygen pulse or 
ventilatory equivalent. The lack of effect on ventilatory 
equivalent at these work loads suggests that anaerobic 
threshold. defined by the sudden increase in ventilation 
relative to oxygen consumption (23), is also not affected by 
digoxin. 
Digoxin effect on ejection fraction during exercise. In 
contrast to the lack of improvement in maximal aerobic 
capacity or submaximal aerobic performance on digoxin for 
the overall sample, an augmentation of left ventricular 
ejection fraction was demonstrable by radionuclide angiog-
raphy. both at submaximal and maximal effort. This increase 
in left ventricular systolic performance on digoxin at maxi-
mal effort occurred in the face of a higher peak systolic blood 
pressure and. thus, a presumably higher afterload than 
during placebo therapy. A recent multicenter trial (8) re-
ported an increase in left ventricular ejection fraction at rest, 
from 26% to 30.4%, without significant improvement in 
treadmill exercise time, with digoxin therapy; in contrast, 
captopril had essentially no effect on left ventricular ejection 
fraction at rest, but significantly increased total exercise 
duration. In that study, however, neither oxygen consump-
tion nor left ventricular performance during exercise was 
measured directly. One week of digoxin treatment had no 
effect on either left ventricular ejection fraction or maximal 
cycle work load in another study (24) of 14 patients with 
coronary artery disease and chronic angina pectoris. The 
presence of normal baseline left ventricular systolic function 
in nearly half of the subjects, the presence of angina and the 
absence of specific congestive heart failure symptoms in 
patients from that study may account for the failure to detect 
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an enhancement of exercise left ventricular ejection fraction 
with digoxin. Arnold et at. (11), using invasive methods in 
patients with congestive heart failure due in most cases to 
cardiomyopathy, found a higher stroke work index and 
lower pulmonary capillary wedge pressure during supine 
submaximal bicycle exercise with digoxin therapy than with 
placebo; Murray et at. (12) demonstrated similar changes 
during upright bicycle exercise. Neither study reported 
whether absolute work performance or oxygen consumption 
improved with digoxin therapy. 
Study limitations. Several limitations of the present study 
should be recognized. Our sample size was small and con-
sisted primarily of patients in New York Heart Association 
functional class II congestive heart failure, with only mod-
erate exercise intolerance. As suggested by our own results, 
patients with greater baseline aerobic impairment (i.e., func-
tional classes III and IV) would likely have greater improve-
ment with digoxin. Similarly, our results obviously do not 
apply to the subset of persons who cannot tolerate with-
drawal of maintenance digoxin therapy. In our experience, 
this subset is small in stable outpatients (I of 12 in the 
current study), which is comparable to the 15% seen in the 
recent multicenter comparison of captopril and digoxin in 
patients with mild to moderate congestive heart failure (21). 
A change in aerobic performance might have required 
more time than the 4-week duration of each phase of our 
study. Arguing against this possibility are the 2- to 4-week 
response times for improvements in peak oxygen consump-
tion noted in prior studies of digitalis (21) or vasodilators in 
heart failure (25,26), as well as our prior inability to detect an 
increase in treadmill duration after 12 weeks of digoxin 
versus placebo therapy (5). Although a higher serum digoxin 
concentration than the mean therapeutic level of 1.4 ng/ml in 
our study might have caused further enhancement of left 
ventricular performance, such a maneuver would also in-
crease the risk of drug toxicity. Finally, our results do not 
exclude the possibility that cardiac output, pulmonary cap-
illary wedge pressure or ventricular volumes may be favor-
ably affected by digoxin during upright exercise. Neverthe-
less, such putative benefits, even if present, would appear to 
have no clinical significance as measured by work perfor-
mance or symptomatic benefit in most patients such as ours. 
Conclusions. Maintenance digoxin therapy causes no dis-
cernible enhancement of aerobic capacity in ambulatory 
patients with coronary artery disease, mild to moderate 
congestive heart failure and systolic dysfunction and who 
are in sinus rhythm. This is so despite measurable improve-
ment in left ventricular performance during exercise. Within 
this sample, however, the change in peak oxygen consump-
tion elicited by digoxin was inversely related to the peak 
oxygen consumption without the drug. Exercise testing with 
measurement of respiratory gas exchange may therefore 
provide a rational basis for selecting ambulatory heart failure 
patients who are likely to benefit from maintenance digoxin 
therapy. 
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